NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»18/10/2009 [Industry news]
China Medical Technologies, Inc.announces the SFDA Approval for its SPR System

China Medical Technologies, Inc. today announced that the Company has received approval for its SPR- based analysis system (the \"SPR System\") from the State Food and Drug Administration of China.

 
China Medical Technologies, Inc. today announced that the Company has received approval for its SPR- based analysis system (the \"SPR System\") from the State Food and Drug Administration of China. The SPR System utilizes Surface Plasmon Resonance (\"SPR\") technology, a leading biosensor technology in molecular biology. SPR technology has been successfully used for the analysis of proteins, nucleic acids and viruses for the past 20 years and has become a powerful platform for life sciences, drug discovery, medicine and food safety. Human papillomavirus (\"HPV\"), a common virus that infects the skin and mucous membranes of humans and causes various kinds of warts as well as cervical cancer, can be detected by adding pathological samples on the HPV-DNA biosensor chip (the \"HPV-DNA chip\") and analyzing the HPV-DNA chip with the SPR System. The SPR System is label-free with high throughput, high speed and a high degree of automation. The detection results can be displayed on a real-time and online basis. The SPR System can be used in various potential clinical diagnostic applications, such as the detection of biomarkers related to infectious diseases, cancers, cardiovascular disorders and immune system disorders. \"We are pleased to receive the SFDA approval for our SPR System on a timely basis,\" commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. \"We have commenced the delivery of our SPR Systems to our large hospital customers and believe that more and more women will benefit from the use of our SPR system and HPV-DNA chips together with our cervical cancer FISH probes, both of which can guide physicians to determine and apply effective treatment in the early stages of cervical diseases to reduce the risk of cervical cancer as well as early detection of cervical cancer.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.